{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:44:24Z","timestamp":1762299864681},"reference-count":16,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2021]]},"DOI":"10.3960\/jslrt.21019","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T22:15:53Z","timestamp":1631225753000},"page":"221-223","source":"Crossref","is-referenced-by-count":2,"title":["Better method for detection of CD30: Immunohistochemistry or flow cytometry?"],"prefix":"10.3960","volume":"61","author":[{"given":"Morihiro","family":"Higashi","sequence":"first","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuko","family":"Takayanagi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Momose","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kizaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichi","family":"Tamaru","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Schwab U, Stein H, Gerdes J <i>et al.<\/i> Production of a monoclonal antibody specific for Hodgkin and Sternberg\u2013Reed cells of Hodgkin\u2019s disease and a subset of normal lymphoid cells. Nature. 1982; 299: 65-67.","DOI":"10.1038\/299065a0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin\u2019s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. 1985. Available at: https:\/\/ashpublications.org\/blood\/article\/66\/4\/848\/164602.","DOI":"10.1182\/blood.V66.4.848.848"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Francisco JA, Cerveny CG, Meyer DL <i>et al.<\/i> cAC10-vcMMAE, an anti-CD30\u2013monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003; 102: 1458-1465.","DOI":"10.1182\/blood-2003-01-0039"},{"key":"4","unstructured":"4 Wahl AF, Klussman K, Thompson JD <i>et al.<\/i> The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin\u2019s disease. Cancer Res. 2002; 62: 3736-3742."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Younes A. CD30-targeted antibody therapy. Curr Opin Oncol. 2011; 23: 587-593.","DOI":"10.1097\/CCO.0b013e32834bb8a7"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Doronina SO, Toki BE, Torgov MY <i>et al.<\/i> Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003; 21: 778-784.","DOI":"10.1038\/nbt832"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Younes A, Gopal AK, Smith SE <i>et al.<\/i> Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012; 30: 2183-2189.","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Pro B, Advani R, Brice P <i>et al.<\/i> Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012; 30: 2190-2196.","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Nizamuddin I, Galvez C, Pro B. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin. Semin Hematol. 2021; 58: 85-94.","DOI":"10.1053\/j.seminhematol.2021.02.006"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Jacobsen ED, Sharman JP, Oki Y <i>et al.<\/i> Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression. Blood. 2015; 125: 1394-1402.","DOI":"10.1182\/blood-2014-09-598763"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Horwitz SM, Advani RH, Bartlett NL <i>et al.<\/i> Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014; 123: 3095-3100.","DOI":"10.1182\/blood-2013-12-542142"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Nakashima M, Watanabe M, Uchimaru K, Horie R. Trogocytosis of ligand-receptor complex and its intracellular transport in CD30 signalling. Biol Cell. 2018; 110: 109-124.","DOI":"10.1111\/boc.201800002"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Hansen HP, Trad A, Dams M <i>et al.<\/i> CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro. Oncotarget. 2016; 7: 30523-30535.","DOI":"10.18632\/oncotarget.8864"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Advani R, Moskowitz AJ, Bartlett NL <i>et al.<\/i> Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021; 138: 427-438.","DOI":"10.1182\/blood.2020009178"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Grewal RK, Chetty M, Abayomi EA, Tomuleasa C, Fromm JR. Use of flow cytometry in the phenotypic diagnosis of hodgkin\u2019s lymphoma. Cytometry B Clin Cytom. 2019; 96: 116-127.","DOI":"10.1002\/cyto.b.21724"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Fromm JR, Thomas A, Wood BL. Flow cytometry can diagnose classical hodgkin lymphoma in lymph nodes with high sensitivity and specificity. Am J Clin Pathol. 2009; 131: 322-332.","DOI":"10.1309\/AJCPW3UN9DYLDSPB"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/4\/61_21019\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T05:37:46Z","timestamp":1640410666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/4\/61_21019\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.21019","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"21019"}}